Vorinostat
CAS 149647-78-9 4 FDA-DMF suppliersSmall Molecule
Overview
Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), is an HDAC inhibitor used in cancer treatment. It is approved for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma.
API suppliers (1)
Suppliers of Vorinostat backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.
- MYLAN LABORATORIES LTD
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Vorinostat expires 18 Mar 2028. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyHematology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.